Receptor tyrosine kinases (RTKs) are key oncogenic drivers and therapeutic targets in cancer. Despite the clinical success of RTK-targeted therapies, primary and acquired resistance mechanisms limit their efficacy. Likewise, in cancer immunotherapy, immune checkpoint inhibitors (ICIs) elicit durable responses in only a subset of patients due to tumor-intrinsic and tumor-extrinsic resistance mechanisms. Combining RTK-targeted therapies with cancer immunotherapy offers a strategy to overcome these limitations by disrupting oncogenic signaling, increasing tumor immunogenicity, and reshaping the tumor microenvironment (TME) to ultimately enhance durable therapy response. This chapter reviews the immunomodulatory functions of cancer-associated RTKs, the rationales for combining RTK-targeted therapies with cancer immunotherapy, and preclinical evidence and clinical evidence that support and explain the efficacy of combination strategies.